The study describes the neuroprotective effect of reelin in neurodegenerative diseases.
Co-directed by Eduardo Soriano and Lluís Pujadas, from the University of Barcelona, and the CIBERNED network, the study has involved Bernat Serra-Vidal, Ernest Giralt and Natàlia Carulla, all three scientists at IRB.
“Correo Farmacéutico” gives news about a donation of 200,00 US$ from the North American association FARA for the gene therapy project devoted to Friedreich’s ataxia developed at IRB and CBM Severo Ochoa.
This project has been promoted from various patients’ associations headed by Genefa.
Read the news in “Correo Farmacéutico” (PDF)
28 January 2014
Scientists at the Institute for Research in Biomedicine (IRB) and the “Centro de Biología Molecular Severo Ochoa” (CBMSO) launched the project two months ago.
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
The support provided by FARA will account for 50% of the project budget of 300,000 euros. Of note, FARA’s funds come from the support of patient families and communities raising funds at a grassroots level and from other International advocates such as FARA – Ireland.
Joan Guinovart, director of IRB Barcelona, Ernest Giralt, head of the Peptides and Proteins lab, and Joan Massagué, External Advisory Board of IRB Barcelona, are once again among the 25 most influential scientists in the ranking drawn up by “El Mundo”.
See the 25 most influential people in science, “El Mundo” (PDF in Spanish)
Meritxell Teixidó, research associate with the Peptides and Proteins group lead by Ernest Giralt, is interviewed on Radio 4 about the gene therapy project on Friedreich's Ataxia that has just started in collaboration between IRB Barcelona and CBMSO in Madrid. This project is financed by donations through the...
Patients and their families united in a single platform, two patients’ associations, and two biomedical research centres join forces in the fight against this hereditary neurological disease for which there is still has no cure.
Scientists at the “Centro de Biología Molecular Severo Ochoa” in Madrid and IRB Barcelona develop a gene therapy project that involves introducing into the body’s cells a correct copy of the defective gene that causes the disease.
Friedreich’s Ataxia affects approximately 2 in every 100,000 people of European origin (Caucasians). In Spain the incidence of this disease is higher, with an estimated 4.7 cases per 100,000 population.
"Ernest Giralt, Uncle Peptide" is the title of an extensive interview with IRB Barcelona researcher and programme coordinator, Ernest Giralt, in the specialized website Sciengeist. Mark Peczuh, the interviewer, is an associate professor of Chemistry at the University of Connecticut who is spending some time in Barcelona with a Fullbright fellowship.
Ernest Giralt talks about his...
The catalan radio station RAC1, offered in its entertainment programme "Tot és possible", an extensive interview with Teresa Tarragó, researcher in IRB Barcelona's Chemistry & Molecular Pharmacology group and...
La Vanguardia reports on the research performed by Ernest Giralt and Pau Gorostiza in a collaboration project between IRB Barcelona and IBEC. Published in the German journal Angewandte Chemie, the study describes how the scientists have designed peptides that can be controlled through exposure to light. This breakthrough in chemical nanobioengineering may allow the future development of drugs that can be activated in specific parts of the body and at given times, thus reducing their side-effects.
More information in the...
Researchers at IRB Barcelona and IBEC achieve photo-switchable molecules to control protein-protein interactions in a remote and non-invasive manner.
These tools will serve as a prototype to develop photo-switchable drugs, whose effects would be limited to a given region and time, thus reducing the side effects on other regions.
The article, cover and “Very Important Paper” of Angewandte Chemie, is a highlighted result of the European project “OpticalBullet”, funded by the European Research Council (ERC) and in which the two institutes participate.